{
    "eid": "2-s2.0-84958653537",
    "title": "Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies",
    "cover-date": "2016-03-01",
    "subject-areas": [
        {
            "$": "Physiology (medical)",
            "@code": "2737"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "Psychiatry and Mental Health",
            "@code": "2738"
        },
        {
            "$": "Pharmacology",
            "@code": "3004"
        }
    ],
    "keywords": [
        "Alzheimer disease",
        "Behavioral symptoms",
        "Cholinesterase inhibitors",
        "Dementia",
        "Donepezil"
    ],
    "authors": [
        "Jeffrey Cummings"
    ],
    "citedby-count": 94,
    "ref-count": 54,
    "ref-list": [
        "Alzheimer's disease",
        "An economic evaluation of donepezil in the treatment of Alzheimer's disease",
        "Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials",
        "Managing behavioural and psychological symptoms in dementia",
        "Behavioral and psychological symptoms of dementia: Part I - Epidemiology, neurobiology, heritability, and evaluation",
        "Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease",
        null,
        "Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type",
        "Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease",
        "Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease",
        "Neurochemical basis for symptomatic treatment of Alzheimer's disease",
        "The cholinergic deficiency syndrome and its therapeutic implications",
        "The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients",
        "Neurological disorders: Public health challenges",
        "Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment",
        "A description of agitation in a nursing home",
        "A new rating scale for Alzheimer's disease",
        "Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment",
        "Behavioral and psychological symptoms of dementia: Part II-treatment",
        "Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence",
        "Behavioral and psychological disturbances in Alzheimer disease: Assessment and treatment",
        "Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type",
        "Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD",
        "Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial",
        "Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials",
        "Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease",
        "Do atypical antipsychotics cause stroke?",
        "Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease",
        "Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease",
        "The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease",
        "Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders",
        "Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease",
        "The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease",
        "A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease",
        "Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial",
        "Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis",
        "Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis",
        "A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease",
        "Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis",
        "A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting",
        "Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study",
        "Perspectives in the management of Alzheimer's disease: Clinical profile of donepezil",
        "High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines",
        "The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease",
        "Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial",
        "Long-term safety and efficacy of donepezil in patients with dementia with lewy bodies: Results from a 52-week, open-label, multicenter extension study",
        "Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled, confirmatory phase III trial",
        "Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies",
        "Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies",
        "The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients",
        "The incremental direct costs associated with behavioral symptoms in AD",
        "Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seongnam",
            "affilname": "Seoul National University Bundang Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taichung",
            "affilname": "Chung Shan Medical University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Tokyo",
            "affilname": "Eisai Co., Ltd.",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Mumbai",
            "affilname": "Fortis Hospital Mahim",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Las Vegas",
            "affilname": "Cleveland Clinic Lou Ruvo Center for Brain Health",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "National Institute of General Medical Sciences",
        "National Institute of General Medical Sciences"
    ]
}